WELCOME TO
aUREALIS NEWS
READ OUR
LATEST PUBLICATION:
Aurealis Therapeutics successfully completes treatment period of its Phase 1 study for AUP-16 in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing
Basel Switzerland, Kuopio Finland – June 14th, 2022. Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that it
ALL PUBLICATIONS
Aurealis Therapeutics Publishes First Study on Four-in-One -Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Basel Switzerland and Kuopio Finland– March 1st, 2022. Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This […]
ReadAurealis Therapeutics to Strengthen Its Management Team by Appointing Dr. Laurent Décory as Chief Operating Officer
Basel Switzerland and Kuopio Finland– February 25th, 2022. Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business […]
ReadAurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
Basel Switzerland, Kuopio Finland, and Shenzhen China – January 28th, 2022. Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis […]
ReadAurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group
Basel Switzerland, Kuopio Finland – May 27th, 2021. Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose […]
ReadAurealis Therapeutics Novel Chronic Wound Treatment to be Presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease on December 15th, 2020
Basel Switzerland, Kuopio Finland – December 15th, 2020. Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for […]
Read